Oppenheimer & Co’s Actinium Pharmaceuticals ATNM Stock Holding History

Oppenheimer & Co’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-467	Closed	-$5K	–	1279
2020 Q2	$5K	Hold	467	–	–	﹤0.01%	1249
2020 Q1	$3K	Hold	467	–	–	﹤0.01%	1189
2019 Q4	$3K	Sell	467 -7,709	-94%	-$53.2K	﹤0.01%	1273
2019 Q3	$56K	Buy	8,176 +300	+4%	+$2.09K	﹤0.01%	1233
2019 Q2	$58K	Buy	7,876 +2,026	+35%	+$20.4K	﹤0.01%	1278
2019 Q1	$84K	Buy	5,850 +2,394	+69%	+$38.2K	﹤0.01%	1311
2018 Q4	$40K	Sell	3,456 -487	-12%	-$8.31K	﹤0.01%	1216
2018 Q3	$87K	Buy	3,943 +1,491	+61%	+$30.4K	﹤0.01%	1312
2018 Q2	$47K	Buy	+2,452	New	+$31.1K	﹤0.01%	1307

Other funds holding ATNM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Oppenheimer & Co's ATNM Position: Q3 2020 in Review

Oppenheimer & Co sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 467 shares — an estimated $5K sold.

Oppenheimer & Co first reported a position in ATNM in Q2 2018 and held it in 9 quarters. The position peaked at $87K in Q3 2018. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

Oppenheimer & Co reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Oppenheimer & Co sold 467 Actinium Pharmaceuticals shares in Q3 2020, an estimated $5K.
Oppenheimer & Co first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 9 quarters.
Oppenheimer & Co's Actinium Pharmaceuticals position peaked at $87K in Q3 2018.
41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on Oppenheimer & Co's 13F filing for Q3 2020, filed 13 Nov 2020.